Non-HDL-cholesterol as valid surrogate to apolipoprotein B<sub>100 </sub>measurement in diabetes: Discriminant Ratio and unbiased equivalence
<p>Abstract</p> <p>Background</p> <p>Apolipoprotein B<sub>100 </sub>(apoB) is a superior indicator of CV risk than total or LDL-C. Non-HDL-C represents a simple surrogate for apoB in hypertriglyceridemic and/or T2DM patients. ApoB and non-HDL-C show high cor...
Main Authors: | Ahn Sylvie A, Sacks Frank M, Hermans Michel P, Rousseau Michel F |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-02-01
|
Series: | Cardiovascular Diabetology |
Online Access: | http://www.cardiab.com/content/10/1/20 |
Similar Items
-
Standardization of Apolipoprotein B, LDL‐Cholesterol, and Non‐HDL‐Cholesterol
by: John H. Contois, et al.
Published: (2023-08-01) -
<it>log</it>(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males
by: Ahn Sylvie A, et al.
Published: (2010-12-01) -
The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls.
by: Parish, S, et al.
Published: (2009) -
Apolipoprotein composition and particle size affect HDL degradation by chymase: effect on cellular cholesterol efflux
by: Miriam Lee, et al.
Published: (2003-03-01) -
Circulating HDL and Non-HDL Associated Apolipoproteins and Breast Cancer Severity
by: Christine Bobin-Dubigeon, et al.
Published: (2022-02-01)